ERBB2 and heart failure: Breast cancer therapy with trastuzumab, an anti-ErbB2 monoclonal antibody, was shown to induce dilated cardiomyopathy and heart failure (Seidman et al., 2002), pointing to a role of NRG-1 signaling in cardiac remodeling.